Japan’s Ministry of Health, Labour and Welfare has approved Sanofi’s Type 2 diabetes treatment Lyxumia (lixsenatide). The medication is already being sold in Mexico, the European Union, and Australia, and is currently under review in the United States. Lyxumia is the first diabetes treatment in its class in Japan. It is used in combination with basal insulin. The drug is a potent and highly selective GLP-1 peptide agonist. Other GLP-1 drugs that are marketed in the United States include Byetta and Victoza. GLP-1 is a naturally occurring peptide that is released within minutes after one eats a meal. It is ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.